AAIC 2025 Abstract
Exploring the role of MRI to optimize the design of clinical trials for progressive supranuclear palsy and corticobasal degeneration
By Jesus Garcia Castro, Lídia Vaqué-Alcázar, Lawren A. VandeVrede, Show 22 more authorsIgnacio Illán-Gala
Study in peopleBiomarkers
Abstract
Background: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are severe neurodegenerative disorders lacking disease‐modifying treatments and validated biomarkers. Clinical trials face challenges due to phenotypic overlap and imperfect clinicopathological correlations.
